February 2024

Bioidea Investor Showcase: EVQLV, Inc.

Bioidea Group presents an exclusive roundtable event featuring emerging technology company EVQLV, Inc. This virtual showcase will be held in a fireside chat format with moderated discussion. A core Bioidea Group team and EVQLV’s CTO will attend the event in-person. Other presenters and attendees will join virtually via Zoom. RSVP at: https://bioidea-evqlv.eventbrite.com


The event is open to investors, biotech professionals, pharma executives, and other healthcare stakeholders. Registrants will receive access to the live video presentation.


  • EVQLV CEO & CTO introduce the company’s computational antibody discovery engine
  • Provide the latest updates around biopharma partnerships
  • Discuss future growth plans
  • Moderator facilitates Q&A


As pioneers in computation-powered antibody design and optimization, EVQLV is unlocking new possibilities for development of biotherapeutics. Their proprietary AI engine models billions of antibody sequence combinations to identify candidates with enhanced target specificity, affinity, and developability compared to traditional discovery methods.

Space for this virtual roundtable is limited. Reserve your spot today to assess the investment opportunities with EVQLV’s AI approach.

About EVQLV, Inc.

EVQLV transforms antibody development for biotechs and pharmaceutical companies using artificial intelligence. EVQLV’s AI-powered Antibody Design Engine uses a wide range of machine learning and software engineering techniques to generate fully-human and developable therapeutic antibody designs